Decoding 11 Analyst Evaluations For Elevance Health
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed evaluations for Elevance Health (NYSE:ELV) over the past quarter, with a trend towards lowering price targets. The average 12-month price target is now $559.91, down 7.03% from the previous $602.27. Despite some positive financial metrics, such as ROE and ROA, Elevance Health faces challenges with net margin and revenue growth compared to industry peers.
October 21, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Elevance Health has received mixed analyst ratings, with a trend towards lowering price targets. The average target is now $559.91, a 7.03% decrease. Despite strong ROE and ROA, the company faces challenges with net margin and revenue growth.
The trend of analysts lowering price targets for Elevance Health suggests a bearish outlook in the short term. The decrease in the average price target by 7.03% indicates reduced expectations for the stock's future performance. While the company shows strong ROE and ROA, its challenges with net margin and revenue growth compared to peers may contribute to the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100